APTARGROUP, INC.
ATRAPI behind this page
ATR Q1 2026 request
Playground key active
/api/financials?ticker=ATR&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 982,868 | 887,305 | +10.8% |
Show Business Segments breakouts |
|||
| Beauty | 363,635 | 305,707 | +18.9% |
| Beauty · Intersegment Elimination | -8,523 | -6,594 | -29.3% |
| Beauty · Operating Segments | 372,158 | 312,301 | +19.2% |
| Closures | 180,673 | 172,131 | +5.0% |
| Closures · Intersegment Elimination | -1,519 | -1,790 | +15.1% |
| Closures · Operating Segments | 182,192 | 173,921 | +4.8% |
| Pharma | 438,560 | 409,467 | +7.1% |
| Pharma · Intersegment Elimination | -348 | -230 | -51.3% |
| Pharma · Operating Segments | 438,908 | 409,697 | +7.1% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -10,390 | -8,614 | -20.6% |
| Operating Segments | 993,258 | 895,919 | +10.9% |
| Cost Of Goods And Service Excluding Depreciation Depletion And Amortization | 630,959 | 550,891 | +14.5% |
Show Business Segments breakouts |
|||
| Beauty · Operating Segments | 271,488 | 224,048 | +21.2% |
| Closures · Operating Segments | 131,883 | 122,391 | +7.8% |
| Pharma · Operating Segments | 228,536 | 205,137 | +11.4% |
| Selling Research And Development And Administrative Expenses | 167,602 | 155,277 | +7.9% |
Show Business Segments breakouts |
|||
| Beauty · Operating Segments | 52,630 | 46,412 | +13.4% |
| Closures · Operating Segments | 24,945 | 23,012 | +8.4% |
| Pharma · Operating Segments | 68,116 | 62,483 | +9.0% |
| Cost Of Goods And Services Sold Depreciation And Amortization | 75,725 | 65,647 | +15.4% |
| Restructuring Charges | 1,086 | 2,042 | -46.8% |
Show Business Segments breakouts |
|||
| Beauty · Operating Segments | 1,301 | 395 | +229.4% |
| Closures · Operating Segments | 249 | 1,352 | -81.6% |
| Pharma · Operating Segments | 5 | 190 | -97.4% |
Show Consolidation Items breakouts |
|||
| Corporate & Other | -469 | 105 | -546.7% |
Show Restructuring Cost And Reserve breakouts |
|||
| Employee Severance | 210 | 192 | +9.4% |
| Professional fees and other costs | 876 | 1,850 | -52.6% |
| Total Costs & Expenses | 875,372 | 773,857 | +13.1% |
| Operating Income | 107,496 | 113,448 | -5.2% |
| Interest Expense | -16,942 | -11,351 | -49.3% |
| Interest Income | 3,642 | 2,814 | +29.4% |
| Gain Loss On Investments | -1,086 | -1,096 | +0.9% |
Show Financial Instrument breakouts |
|||
| Preferred Stock · PureCycle | -1,086 | -1,096 | +0.9% |
| Income Loss From Equity Method Investments | 714 | 2,086 | -65.8% |
| Other Non-Operating Income (Expense) | -53 | 114 | -146.5% |
Show Derivative Risk breakouts |
|||
| Currency Swap · Cash Flow Hedging | -53 | — | — |
| Nonoperating Income Expense Including Income Loss From Equity Method Investments | -13,725 | -7,433 | -84.6% |
| Income Before Taxes | 93,771 | 106,015 | -11.5% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment Net Prior Service Cost Credit · Reclassification Out Of Accumulated Other Comprehensive Income | -27 | -23 | -17.4% |
| Accumulated Defined Benefit Plans Adjustment Net Unamortized Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income | -132 | -169 | +21.9% |
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -159 | -192 | +17.2% |
| Income Tax Expense (Benefit) | 21,004 | 27,352 | -23.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -50 | -60 | +16.7% |
| Net Income | 72,767 | 78,663 | -7.5% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -109 | -132 | +17.4% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -109 | -132 | +17.4% |
| Net Income Loss Attributable To Nonredeemable Noncontrolling Interest | -4 | 135 | -103.0% |
| Net Income Loss Attributable To Redeemable Noncontrolling Interest | -89 | — | — |
| Net Income | 72,674 | 78,798 | -7.8% |
| EPS (Basic) | 1.13 | 1.19 | -5.0% |
| EPS (Diluted) | 1.12 | 1.17 | -4.3% |
| Wtd Avg Shares (Basic) | 64,050 | 66,271 | -3.4% |
| Wtd Avg Shares (Diluted) | 64,834 | 67,491 | -3.9% |
| Common Stock Dividends Per Share Declared | 0.48 | 0.45 | +6.7% |
| Comprehensive Income | 60,416 | 157,417 | -61.6% |
| Net Income Loss Available To Common Stockholders Basic | 72,674 | 78,798 | -7.8% |
| Revenue From Contract With Customer Including Assessed Tax | 982,868 | 887,305 | +10.8% |
Show Business Segments breakouts |
|||
| Beauty | 363,635 | 305,707 | +18.9% |
| Beauty · Asia | 37,711 | 20,015 | +88.4% |
| Beauty · Europe | 222,876 | 187,909 | +18.6% |
| Beauty · Latin America | 46,279 | 39,586 | +16.9% |
| Beauty · North America | 56,769 | 58,197 | -2.5% |
| Closures | 180,673 | 172,131 | +5.0% |
| Closures · Asia | 17,802 | 16,541 | +7.6% |
| Closures · Europe | 61,288 | 52,044 | +17.8% |
| Closures · Latin America | 20,000 | 20,947 | -4.5% |
| Closures · North America | 81,583 | 82,599 | -1.2% |
| Pharma | 438,560 | 409,467 | +7.1% |
| Pharma · Asia | 50,732 | 57,132 | -11.2% |
| Pharma · Europe | 226,686 | 198,693 | +14.1% |
| Pharma · Latin America | 19,688 | 11,981 | +64.3% |
| Pharma · North America | 141,454 | 141,661 | -0.1% |
Show Geography breakouts |
|||
| Asia | 106,245 | 93,688 | +13.4% |
| Europe | 510,850 | 438,646 | +16.5% |
| Latin America | 85,967 | 72,514 | +18.6% |
| North America | 279,806 | 282,457 | -0.9% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 222,529 | 125,839 | +76.8% |
| Short-Term Investments | 6,948 | 10,982 | -36.7% |
| Accounts Notes And Loans Receivable Net Current | 833,268 | 742,703 | +12.2% |
| Inventory | 551,482 | 483,520 | +14.1% |
| Prepaid Expenses & Other Current Assets | 154,045 | 148,723 | +3.6% |
| Total Current Assets | 1,768,272 | 1,511,767 | +17.0% |
| Non-Current Assets | |||
| Long Term Investments | 130,761 | 147,686 | -11.5% |
| Goodwill | 1,072,560 | 954,292 | +12.4% |
Show Business Segments breakouts |
|||
| Beauty | 370,158 | — | — |
| Closures | 168,063 | — | — |
| Pharma | 534,339 | — | — |
| Intangible Assets | 244,508 | 249,960 | -2.2% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 148,416 | 153,036 | -3.0% |
| License agreements and other | 22,902 | 17,888 | +28.0% |
| Patented Technology | 54,274 | 57,463 | -5.5% |
| Patents | 14,590 | 15,802 | -7.7% |
| Trademarks And Trade Names | 4,326 | 5,771 | -25.0% |
| Operating Lease Right-of-Use Assets | 61,234 | 66,567 | -8.0% |
| Other Assets Miscellaneous Noncurrent | 159,519 | 107,418 | +48.5% |
| Other Non-Current Assets | 1,668,582 | 1,525,923 | +9.3% |
| Total Assets | 5,097,783 | 4,527,088 | +12.6% |
| Other Assets | |||
| Land | 31,040 | 29,178 | +6.4% |
| Buildings And Improvements Gross | 882,451 | 785,735 | +12.3% |
| Machinery And Equipment Gross | 3,675,261 | 3,276,867 | +12.2% |
| Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization | 4,588,752 | 4,091,780 | +12.1% |
| Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization | -2,927,823 | -2,602,382 | -12.5% |
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1,660,929 | 1,489,398 | +11.5% |
| Current Liabilities | |||
| Short Term Borrowings | 189,046 | 159,170 | +18.8% |
Show Short Term Debt Type breakouts |
|||
| Line Of Credit | 157,274 | 159,089 | -1.1% |
| Short-term obligations 1.50% to 3.00% | 31,772 | — | — |
| Long Term Debt And Capital Lease Obligations Current | 33,120 | 286,216 | -88.4% |
| Accounts Payable Accrued Liabilities And Derivative Liabilities Current | 840,867 | 762,638 | +10.3% |
| Total Current Liabilities | 1,063,033 | 1,208,024 | -12.0% |
| Deferred Revenue (Current) | 79,798 | 80,000 | -0.3% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 17,285 | 14,347 | +20.5% |
| Pension And Other Postretirement Plan Liabilities And Deferred Compensation Liability Noncurrent | 64,145 | 67,344 | -4.8% |
| Operating Lease Liabilities | 44,013 | 50,850 | -13.4% |
| Other Liabilities And Deferred Revenue Noncurrent | 91,686 | 73,824 | +24.2% |
| Deferred Liabilities And Other Liabilities Noncurrent | 217,129 | 206,365 | +5.2% |
| Contract With Customer Liability Noncurrent | 47,838 | 46,400 | +3.1% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 1,143,370 | 561,165 | +103.7% |
| Stockholders' Equity | |||
| Redeemable Noncontrolling Interest Equity Carrying Amount | 26,694 | — | — |
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | 26,694 | — | — |
| Common Stock | 731 | 726 | +0.7% |
| Additional Paid In Capital Common Stock | 1,192,705 | 1,142,620 | +4.4% |
| Retained Earnings | 2,684,382 | 2,419,414 | +11.0% |
| Accumulated Other Comprehensive Income | -198,716 | -350,858 | +43.4% |
| Treasury Stock Common Value | -1,049,607 | -674,344 | -55.6% |
| Total Stockholders' Equity | 2,629,495 | — | — |
| Minority Interest | 18,062 | 13,976 | +29.2% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 2,647,557 | 2,551,534 | +3.8% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 21,678 | 5,722 | +278.9% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -20,503 | -12,815 | -60.0% |
| Accumulated Other Comprehensive Income | -198,716 | -350,858 | +43.4% |
| Accumulated Translation Adjustment | -199,891 | -343,765 | +41.9% |
| Additional Paid In Capital | 1,192,705 | 1,142,620 | +4.4% |
| Common Stock | 731 | 726 | +0.7% |
| Noncontrolling Interest | 18,062 | 13,976 | +29.2% |
| Retained Earnings | 2,684,382 | 2,419,414 | +11.0% |
| Treasury Stock Common | -1,049,607 | -674,344 | -55.6% |
| Total Liabilities & Equity | 5,097,783 | 4,527,088 | +12.6% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 64,310 | 54,903 | +17.1% |
| Adjustment For Amortization | 11,415 | 10,744 | +6.2% |
| Stock-Based Compensation | 16,764 | 19,193 | -12.7% |
| Provision For Doubtful Accounts | 644 | 35 | +1740.0% |
| Gain Loss On Disposition Of Assets1 | 81 | -271 | +129.9% |
| Equity Securities Fv Ni Gain Loss | 1,086 | 1,096 | -0.9% |
| Deferred Income Taxes | -4,567 | -1,860 | -145.5% |
| Employee Benefits And Share Based Compensation | 3,443 | 3,277 | +5.1% |
| Income Loss From Equity Method Investments Net Of Dividends Or Distributions | -714 | -2,086 | +65.8% |
| Asset Impairment Charges | 901 | — | — |
| Increase Decrease In Accounts And Other Receivables | -33,030 | -69,247 | +52.3% |
| Change in Inventory | -16,943 | -6,043 | -180.4% |
| Change in Prepaid & Other Assets | -12,393 | -12,617 | +1.8% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 36,422 | 33,324 | +9.3% |
| Increase Decrease In Accrued Income Taxes Payable | 103 | -7,195 | +101.4% |
| Increase Decrease In Pension And Postretirement Obligations | -15,271 | -11,751 | -30.0% |
| Increase Decrease In Other Operating Capital Net | -6,324 | -7,423 | +14.8% |
| Net Cash from Operations | 118,694 | 82,742 | +43.5% |
| Depreciation & Amortization | 75,725 | 65,647 | +15.4% |
Show Business Segments breakouts |
|||
| Beauty · Operating Segments | 24,723 | 20,062 | +23.2% |
| Closures · Operating Segments | 14,224 | 13,575 | +4.8% |
| Pharma · Operating Segments | 35,643 | 31,148 | +14.4% |
Show Consolidation Items breakouts |
|||
| Corporate & Other | 1,135 | 862 | +31.7% |
| Operating Segments | 74,590 | 64,785 | +15.1% |
| Investing Activities | |||
| Capital Expenditures | -65,396 | -56,862 | -15.0% |
| Proceeds From Sale Of Property Plant And Equipment | 1,327 | 79 | +1579.7% |
| Payments For Proceeds From Short Term Investments | -103 | -88 | -17.0% |
| Payments To Acquire Intangible Assets | -592 | -2,475 | +76.1% |
| Increase Decrease In Notes Receivables | -335 | 2,714 | -112.3% |
| Net Cash from Investing | -65,099 | -56,632 | -15.0% |
| Financing Activities | |||
| Proceeds From Notes Payable | 2,930 | 79 | +3608.9% |
| Repayments Of Notes Payable | -2,895 | — | — |
| Proceeds From Repayments Of Lines Of Credit | 7,000 | -23,880 | +129.3% |
| Proceeds From Issuance Of Long Term Debt | 5,037 | 124 | +3962.1% |
| Repayments Of Long Term Debt | -127,927 | -4,552 | -2710.3% |
| Payment For Contingent Consideration Liability Financing Activities | -2,197 | — | — |
| Payments Of Dividends Common Stock | -30,920 | -29,923 | -3.3% |
| Proceeds From Stock Options Exercised | 18,516 | 3,375 | +448.6% |
| Share Repurchases | -99,973 | -80,000 | -25.0% |
| Proceeds From Minority Shareholders | 89 | — | — |
| Net Cash from Financing | -230,340 | -134,777 | -70.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -3,150 | 10,662 | -129.5% |
| Net Change in Cash | -179,895 | -98,005 | -83.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 224,954 | 125,839 | +78.8% |
| Restricted Cash And Cash Equivalents At Carrying Value | 606 | — | — |
| Restricted Cash And Cash Equivalents Noncurrent | 1,819 | — | — |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.